Kalvista Pharmaceuticals (NASDAQ:KALV) issued its earnings results on Monday. The specialty pharmaceutical company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.07), Fidelity Earnings reports. Kalvista Pharmaceuticals had a negative return on equity of 25.94% and a negative net margin of 127.20%. The company had revenue of $2.93 million for the quarter, compared to analyst estimates of $3.64 million.
Shares of KALV opened at $17.35 on Thursday. The firm’s 50 day moving average price is $19.92. Kalvista Pharmaceuticals has a 1 year low of $7.95 and a 1 year high of $34.92.
In related news, CEO Thomas Andrew Crockett sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $17.04, for a total transaction of $170,400.00. Following the transaction, the chief executive officer now owns 248,510 shares of the company’s stock, valued at $4,234,610.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Benjamin L. Palleiko sold 3,073 shares of the company’s stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $25.70, for a total transaction of $78,976.10. Following the transaction, the chief financial officer now directly owns 33,573 shares in the company, valued at approximately $862,826.10. The disclosure for this sale can be found here. Insiders have sold 20,428 shares of company stock worth $440,900 in the last three months. Insiders own 38.40% of the company’s stock.
Several research analysts have weighed in on the stock. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Zacks Investment Research lowered shares of H&E Equipment Services from a “hold” rating to a “sell” rating in a research report on Wednesday. BidaskClub lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 9th. TheStreet upgraded shares of VEON from a “d+” rating to a “c-” rating in a research report on Thursday, July 11th. Finally, Needham & Company LLC increased their price target on shares of Zuora from $27.00 to $30.00 and gave the company a “strong-buy” rating in a research report on Wednesday, March 20th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $29.40.
About Kalvista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Further Reading: What is a death cross?
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.